Philippe Martin

Philippe Martin

Drug Development Consultant

  • 20 years of biotechnology and pharmaceutical industry experience developing and commercializing innovative therapies in the fields of immunology, oncology, and neurology.
  • Chief of Clinical Development & Operations at BioAtla, Inc., overseeing the development of pre-clinical and clinical assets
  • Previously, at Celgene, he led the of Otezla®. Prior at Schering-Plough he led the REMICADE/ SIMPONI lifecycle strategy, development and regulatory approvals
Dr. Albert Garcia-Romeu, PhD

Dr. Albert Garcia-Romeu, PhD

Member, R&D Advisory Board

  • Assistant Professor of Psychiatry and Behavioral Sciences at the Johns Hopkins University School of Medicine
  • Has conducted more than 90 high-dose psilocybin sessions in the laboratory since 2012
  • Founding member of the Johns Hopkins Center for Psychedelic and Consciousness Research